Publications

 

 

Shim HS, Horner JW, Wu CJ, et al. Telomerase Reverse Transcriptase Preserves Neuron Survival and Cognition in Alzheimer's Disease Models. Nat Aging. 2021;1(12):1162-1174. 

 

Hou P, Ma X, Yang Z, et al. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Genes Dev. 2021;35(19-20):1327-1332

 

Yoshihama Y, LaBella KA, Kim E, et al. AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase. Proc Natl Acad Sci U S A. 2021;118(36):e2026324118. doi:10.1073/pnas.2026324118

 

Chakravarti D, Lee R, Multani AS, et al. Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proc Natl Acad Sci U S A. 2021;118(29):e2024853118. doi:10.1073/pnas.2024853118

 

Chakravarti D, Hu B, Mao X, et al. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nat Commun. 2020;11(1):4766. Published 2020 Sep 21. doi:10.1038/s41467-020-18420-w

 

Zhao D, Cai L, Lu X, et al. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020;10(9):1374-1387. doi:10.1158/2159-8290.CD-19-1352

 

Hou P, Kapoor A, Zhang Q, et al. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discov. 2020;10(7):1058-1077. doi:10.1158/2159-8290.CD-19-0597

 

Dey P, Li J, Zhang J, et al. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discov. 2020;10(4):608-625. doi:10.1158/2159-8290.CD-19-0297

 

Chen P, Hsu WH, Chang A, et al. Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment. Cancer Discov. 2020;10(3):371-381. doi:10.1158/2159-8290.CD-19-0400

 

Hou P, Ma X, Zhang Q, et al. USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. Genes Dev. 2019;33(19-20):1361-1366. doi:10.1101/gad.326314.119

 

Liao W, Overman MJ, Boutin AT, et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35(4):559-572.e7. doi:10.1016/j.ccell.2019.02.008

 

Zhao D, Lu X, Wang G, Lan Z, Liao W, et al. Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN-deficient cancer. Nature 542(7642): 484-488, 2017.

 

Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 31(4): 370-382, 2017. 

 

Dey P, Baddour J, Muller F, Wu CC, Wang H, et al.  Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer.  Nature 542(7639): 119-123, 2017.

 

Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, et al.  Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell 167(5): 1281-1295, 2016.

 

Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, et al.  Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5): 644-657, 2015. 

 

Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, et al.  Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411): 337-342, 2012.

 

Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3): 656-770, 2012.

 

Hu J, Hwang SS, Liesa M, Gan B, Sahin E, et al.  Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148(4): 651-663, 2012.

 

Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35(11-12):787-820. doi:10.1101/gad.348226.120

 

Han J, DePinho RA, Maitra A. Single-cell RNA sequencing in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2021;18(7):451-452. doi:10.1038/s41575-021-00471-z

 

Dey P, Kimmelman AC, DePinho RA. Metabolic Codependencies in the Tumor Microenvironment. Cancer Discov. 2021;11(5):1067-1081. doi:10.1158/2159-8290.CD-20-1211

 

Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. Cell. 2021;184(2):306-322. doi:10.1016/j.cell.2020.12.028

 

Chen P, Hsu WH, Han J, Xia Y, DePinho RA. Cancer Stemness Meets Immunity: From Mechanism to Therapy. Cell Rep. 2021;34(1):108597. doi:10.1016/j.celrep.2020.108597

 

Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 32(17-18):1105-1140, 2018.

 

Zhao D, DePinho RA.  Synthetic essentiality: Targeting tumor suppressor deficiencies in cancer. Bioessays. 39(8), 2017. doi.org/10.1002/bies.201700076

 

Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA.  Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 30(4): 355-385, 2016.

 

Muller FL, Aquilanti EA, DePinho RA.  Collateral Lethality: A new therapeutic strategy in oncology. Trends Cancer 1(3): 161-173, 2015.

 

Sahin E, DePinho RA. Axis of ageing: telomeres, p53 and mitochondria. Nat Rev Mol Cell Biol. 13(6): 397-404, 2012.

 

Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26(8): 756-784, 2012.

 

Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 31(1): 9-18, 2010.

 

Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA.  Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15(11): 1311-1333, 2001.

 

DePinho RA. The age of cancer. Nature 408(6809): 248-254, 2000.